Diego Medina Valencia, Mayra Estacio, Ana Clarete, S. Timaran, Eliana Manzi, Estefanía Beltrán Gomez, A. Franco
{"title":"Desenlace de los pacientes pediátricos con falla medular tratados en un centro de alta complejidad","authors":"Diego Medina Valencia, Mayra Estacio, Ana Clarete, S. Timaran, Eliana Manzi, Estefanía Beltrán Gomez, A. Franco","doi":"10.32641/rchped.v91i4.1579","DOIUrl":null,"url":null,"abstract":"Bone marrow failure (BMF) syndromes are rare disorders with an annual incidence of 2-4 cases per million. Treatment options include immunosuppressive therapy (IST) and hematopoietic stem cell transplantation (HSCT). Objective: To analyze the outcomes of pediatric patients diagnosed with BMF treated in a tertiary care center. Patients and Method: Retrospective study of pediatric patients diagnosed with BMF who consulted at Fundacion Valle de Lili, Cali. Descriptive statistical analysis was performed according to Acquired BMF (ABMF) and Inherited BMF (IBMF). The outcomes include treatment, complications, overall survival (OS) in transplant patients, calculated using the KaplanMeier method. Results: We included 24 patients with BMF, average age 6.5 ± 4 years, and 50% were women. 58% presented IBMF, 9 with Fanconi anemia (FA), 2 dyskeratosis congenita, 2 congenital amegakaryocytic thrombocytopenia, and 1 presented Diamond-Blackfan anemia. 12 patients treated with HSCT had a 5-year OS of 83%. ABMF represented 42%. 6 patients received IST-HSCT, 3 received IST, and 1 received HSCT. The OS of the IST-HSCT group was 86%. Six patients died, four of them related to infection. Conclusions: In this series, there was a higher number of cases with IBMF. The OS of patients treated with HSCT is similar to that reported in recent studies. The most frequent cause of death was of infectious origin which has also been previously reported. The treatment established in the patients showed favorable results in a Latin American tertiary care center.","PeriodicalId":46023,"journal":{"name":"Revista Chilena de Pediatria-Chile","volume":"91 1","pages":"545-552"},"PeriodicalIF":0.0000,"publicationDate":"2020-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Chilena de Pediatria-Chile","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32641/rchped.v91i4.1579","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Bone marrow failure (BMF) syndromes are rare disorders with an annual incidence of 2-4 cases per million. Treatment options include immunosuppressive therapy (IST) and hematopoietic stem cell transplantation (HSCT). Objective: To analyze the outcomes of pediatric patients diagnosed with BMF treated in a tertiary care center. Patients and Method: Retrospective study of pediatric patients diagnosed with BMF who consulted at Fundacion Valle de Lili, Cali. Descriptive statistical analysis was performed according to Acquired BMF (ABMF) and Inherited BMF (IBMF). The outcomes include treatment, complications, overall survival (OS) in transplant patients, calculated using the KaplanMeier method. Results: We included 24 patients with BMF, average age 6.5 ± 4 years, and 50% were women. 58% presented IBMF, 9 with Fanconi anemia (FA), 2 dyskeratosis congenita, 2 congenital amegakaryocytic thrombocytopenia, and 1 presented Diamond-Blackfan anemia. 12 patients treated with HSCT had a 5-year OS of 83%. ABMF represented 42%. 6 patients received IST-HSCT, 3 received IST, and 1 received HSCT. The OS of the IST-HSCT group was 86%. Six patients died, four of them related to infection. Conclusions: In this series, there was a higher number of cases with IBMF. The OS of patients treated with HSCT is similar to that reported in recent studies. The most frequent cause of death was of infectious origin which has also been previously reported. The treatment established in the patients showed favorable results in a Latin American tertiary care center.
骨髓衰竭(BMF)综合征是罕见的疾病,年发病率为每百万人2-4例。治疗方案包括免疫抑制疗法(IST)和造血干细胞移植(HSCT)。目的:分析诊断为BMF的儿科患者在三级保健中心治疗的结果。患者和方法:对在加州Lili foundation Valle de Lili就诊的诊断为BMF的儿科患者进行回顾性研究。根据获得性骨密度(ABMF)和遗传性骨密度(IBMF)进行描述性统计分析。结果包括治疗、并发症、移植患者的总生存期(OS),使用KaplanMeier方法计算。结果:纳入BMF患者24例,平均年龄6.5±4岁,女性占50%。IBMF占58%,Fanconi贫血(FA) 9例,先天性角化不良2例,先天性无核细胞性血小板减少2例,Diamond-Blackfan贫血1例。12例接受造血干细胞移植的患者5年总生存率为83%。ABMF占42%。IST-HSCT 6例,IST 3例,HSCT 1例。IST-HSCT组总生存率为86%。6名患者死亡,其中4人与感染有关。结论:在这个系列中,有更多的IBMF病例。移植患者的OS与近期研究报道相似。最常见的死亡原因是感染,这在以前也有过报道。在拉丁美洲三级保健中心建立的患者治疗显示出良好的结果。